360° SearchNetwork Hot Spots Trends Time Series

PAREXEL

Type: Company

Name: PAREXEL

First reported 11 hours ago - Updated 11 hours ago - 1 reports

Clinical Development Outsourcing and Strategic Partnerships

Source: Applied Clinical TrialsEmailPrintSaveLicenseJosh Schultz, Corporate VP at ParexelLast month, Parexel took advantage of IIR's Partnerships in Clinical Trials Conference to release its funded, but independently developed, report "Strategic Partnerships ... [Published Applied Clinical Trials - 11 hours ago]

Entities: PAREXEL, Clinical trials, Evolution

First reported 16 hours ago - Updated 14 hours ago - 1 reports

Sony Corporation

New Stock Coverage: Future Sunny for Sony

It was anything but a Manic Monday on Wall Street, with markets moving nowhere fast in desultory trading action, but for David Karp, born the year The Bangles released their best-selling song, Merger Monday was music to his ears. Tumblrs 20-something ... [Published Minyanville - 16 hours ago]

Entities: Sony Corporation, Cray Incorporated, Stocks, Piper Jaffray Companies

First reported 16 hours ago - Updated 16 hours ago - 1 reports

UPDATE: ISI Initiates Coverage on PAREXEL With a Neutral Rating

In a report published on Tuesday, International Strategy & Investment Group analyst Ross Muken initiated coverage on PAREXEL (NASDAQ: PRXL) with a Neutral rating and a $50 PT.In the report, ISI noted that, "Impressive top-line growth at PRXL (20% in FY13E) ... [Published Benzinga.com - 16 hours ago]

Entities: PAREXEL, Perceptive Informatics, Ross Muken

First reported May 17 2013 - Updated May 17 2013 - 1 reports

FDA Food & Drug Administration

FDA Expectations for Supplier Management

James Stumpff, Principal Consultant at PAREXEL discusses supplier management and FDA's expectations.Pharmaceutical TechnologyVolume 37, Issue 5, pp. 94Q How can FDA-regulated industries best manage their suppliers? What does FDA expect?A. A robust system ... [Published Pharmaceutical Technology - May 17 2013]

Entities: FDA Food & Drug Administration, Quality Systems Inc, Drugs, PAREXEL

First reported May 09 2013 - Updated May 10 2013 - 2 reports

Covance

Quintiles Climbs 5% In Debut In A Busy Day, Week For IPOs

Quintiles Transnational (Q) , the drug clinical trials giant, got a decent reception on the NYSE Thursday in a busy day for IPOs.The largest contract research organization's shareholders late Wednesday decided to offer 4 million shares more than previously ... [Published Yahoo! Finance - May 10 2013]

Entities: Quintiles, IPOs, Covance, Computer Networking, Clinical trials

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Endocyte Inc

Endocyte appoints Parexel’s Scot Harper to oversee clinical trials

He also previously served at Novartis and LillyEndocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma company.Dr Harper (pictured right) joins from (CRO) Parexel, ... [Published PMLive - May 09 2013]

Entities: Endocyte Inc, PAREXEL, Clinical trials, Appointed, Oncology

First reported May 07 2013 - Updated May 07 2013 - 1 reports

PAREXEL Announces Acquisition of HERON Group LTD

Company has acquired all of the outstanding equity securities of the HERON. ... [Published Technology Networks - May 07 2013]

Entities: PAREXEL, Heron, Acquisition

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Strong revenue, profit growth for Parexel in Q3

Parexel delivered another strong quarter of growth in revenue and operating profits, ahead of analysts’ estimates, for the three months ended 31 March 2013.The company also bolstered its capabilities in the market-access space by acquiring Heron Group, ... [Published Pharma Times - May 02 2013]

Entities: PAREXEL, Heron, US 1 Industries Inc

First reported May 01 2013 - Updated May 02 2013 - 2 reports

CenterWatch Study Rates CROs

Related Searches: Clinical Trial • CRO News • PPD • •Related Breaking NewsCenterWatch has conducted a study of more than 2,000 global investigative sites rating the best CROs to work for. Investigative sites gave the highest ratings to their clinical ... [Published Contract Pharma - May 01 2013]

Entities: Covance, Quintiles, Clinical trials, INC Research

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Parexel Sees Strong Growth in Fiscal 3Q; Raising Firm's Fair Value on Higher Growth Trajectory

At this time, we have not yet assigned a Stewardship Grade to this mutual fund. We will be adding more Stewardship Grades over the next several months, so be sure to check back in the future.If you would like to learn more about how we assign Stewardship ... [Published Morningstar.com - May 01 2013]

Entities: PAREXEL, Mutual Fund

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Parexel acquires Heron Group

Parexel, a US-based clinical research organization, has acquired the equity securities of the Heron Group, a life sciences consultancy which provides evidence-based commercialization services to support biopharmaceutical companies throughout the lifecycle ... [Published PBR - News - May 01 2013]

Entities: PAREXEL, Heron, Life Science

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

PAREXEL Makes an Acquisition

The single, easiest way to keep track of all the stocks that matter...Your own personalized stock watchlist!It's a 100% FREE Motley Fool service... The immediate cost of the acquisition was $24 million, which was funded through PAREXEL's existing cash ... [Published Motley Fool - Apr 30 2013]

Entities: PAREXEL, Acquisition, Heron

Quotes

In fact, Schultz noted some underlying factors that could actually benefit small pharma in a strategic partnership. "They are small, so they can implement faster. They traditionally do not have a complicated tangle of legacy systems that need to be integrated, so that allows for faster start-up and they can take advantage of newer technologies."

Clinical Development Outsourcing and Strategic Partnerships [Published Applied Clinical Trials - 11 hours ago]

In the report, ISI noted that, "Impressive top-line growth at PRXL (20% in FY13E) has been driven by a robust re-acceleration of biopharma development spending coming out of the recession as well as the contribution from a number of large strategic contracts (including PFE, LLY, BMY). While growth will moderate to some extent in FY14-15 as evidenced by recent book-to-bill declines (1.6x in FY12 to 1.2x in 1H'13), we contend that increased outsourcing (reaching ~50% penetration in the medium term), low-to-mid-single digit biopharma R&D growth, and share gains will drive double-digit top-line growth. Further, differentiated offerings such as PCMS and Perceptive Informatics also provide PRXL with cross-selling opportunities. Finally, we expect operating margins to expand ~250 bps over the next three years (as revenue from strategic partnerships comes to scale and labor mix become more favorable), driving 20% earnings growth. Despite the potential tailwinds, we contend that the current valuation is already reflective of enthusiasm for these opportunities and thus we are initiating coverage of PRXL with a Neutral rating and $50.00 PT, which equates to ~20x CY14 EPS."

UPDATE: ISI Initiates Coverage on PAREXEL With a Neutral Rating [Published Benzinga.com - 16 hours ago]

...When it didn't arrive, she got excuses: It was a "mess"; they'd be "embarrassed." She recalls begging, "I don't care if it's written on the back of toilet paper. Just send me something." But it never arrived

The epic inside story of fraud at a generic Lipitor giant [Published Fortune - May 15 2013]

More Content

sort by: Date \| Relevance
Clinical Development Outsourcing and Strategic ... [Published Applied Clinical Trials - 11 hours ago]
UPDATE: ISI Initiates Coverage on PAREXEL With ... [Published Benzinga.com - 16 hours ago]
New Stock Coverage: Future Sunny for Sony [Published Minyanville - 16 hours ago]
FDA Expectations for Supplier Management [Published Pharmaceutical Technology - May 17 2013]
Vince & Associates Clinical Research acquired b... [Published Center Watch - May 16 2013]
Edgemont Capital Completes Sale Of Vince & Asso... [Published TickerTech.com - May 15 2013]
The epic inside story of fraud at a generic Lip... [Published Fortune - May 15 2013]
IT outfit Instem acquires Logos to penetrate ea... [Published FiercePharma - May 13 2013]
4 High Flyers You've Never Heard Of [Published InvestorPlace.com - May 11 2013]
Quintiles Climbs 5% In Debut In A Busy Day, Wee... [Published Yahoo! Finance - May 10 2013]
Quintiles IPO Cleans Up As New Issues Multiply [Published Investors Business Daily - May 09 2013]
Top Insider Trades: SPB, PBI, GNRC, VOCS [Published TheStreet.com - May 09 2013]
Endocyte appoints Parexel’s Scot Harper to over... [Published PMLive - May 09 2013]
PAREXEL Announces Acquisition of HERON Group LTD [Published Technology Networks - May 07 2013]
Strong revenue, profit growth for Parexel in Q3 [Published Pharma Times - May 02 2013]
CenterWatch Study Rates CROs [Published Contract Pharma - May 01 2013]
Investigative Sites Rate INC Research, Inc., PP... [Published BioSpace - May 01 2013]
Investigative Sites Rate INC Research, Inc., PP... [Published BioSpace - May 01 2013]
Parexel Sees Strong Growth in Fiscal 3Q; Raisin... [Published Morningstar.com - May 01 2013]
2013 Partnerships in Clinical Trials Awards Win... [Published Partnerships in Clinical Trials - May 01 2013]
Parexel acquires Heron Group [Published PBR - News - May 01 2013]
Investigative Sites Rate INC Research, PPD, inV... [Published NewsBlaze - May 01 2013]
PAREXEL Makes an Acquisition [Published Motley Fool - Apr 30 2013]
PAREXEL (PRXL): Q1 EPS of $0.50 beats by $0.10.... [Published Seeking Alpha - Apr 30 2013]
Icon Beats Q4 Estimates, Prepares for Revenue U... [Published Outsourcing Pharma - Apr 29 2013]
ICON Honored with 'Partnership Pioneers of the ... [Published Zecco - Apr 29 2013]
#PCTUS 2013: How to improve your outsourcing pa... [Published Partnerships in Clinical Trials - Apr 24 2013]
ICON Wins ‘Partnership Pioneers of the Year’ Aw... [Published EON Science - Apr 24 2013]
ICON Wins ‘Partnership Pioneers of the Year’ Aw... [Published Business Wire Health News - Apr 24 2013]
ISR’s CRO Quality Benchmarking Study Reports DC... [Published BioPortfolio - Apr 23 2013]

Blogs

sort by: Date \| Relevance
2013 Partnerships in Clinical Trials Awards Win... [Published Partnerships in Clinical Trials - May 01 2013] Last week at Partnerships in Clinical Trials , we presented the 3rd Annual Partnerships in Clinical Trials awards.Congratulations to our winners! The Pfizer/PAREXELl/ICON Team Third Annual Partnerships Awards Winners Clinical Trial Innovator of ...
Parexel acquires Heron Group [Published PBR - News - May 01 2013] Parexel, a US-based clinical research organization, has acquired the equity securities of the Heron Group, a life sciences consultancy which provides evidence-based commercialization services to support biopharmaceutical companies throughout the lifecycle ...
#PCTUS 2013: How to improve your outsourcing pa... [Published Partnerships in Clinical Trials - Apr 24 2013] We started out the afternoon with the Avoca Update. This year's survey focused on risk sharing. One of the major findings to come out of the survey was that when providers are penalized, there is generally a more negative experience. Relationships ...
Up And Down The Ladder… Job Changes [Published Pharmalot - Jan 25 2013] Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them . Don’t be shy. Everyone wants ...
Pharmalot… Pharmalittle… The Weekend Nears [Published Pharmalot - Jan 04 2013] And so, a short work week is about to come to a close. We barely had time to resume our groove and already we can daydream about weekend plans. As usual, the agenda is quite modest. We expect to spend time with assorted short people and catch up on ...

Press Releases

sort by: Date \| Relevance
ICON Wins ‘Partnership Pioneers of the Year’ Aw... [Published EON Science - Apr 24 2013]
ICON Wins ‘Partnership Pioneers of the Year’ Aw... [Published Business Wire Health News - Apr 24 2013]
Healthcare Contract Research Outsourcing Market... [Published PR.com Press Releases - Mar 10 2013]
Novel Health Strategies Announces Publication o... [Published PR.com Press Releases - Jan 24 2013]
Le Groupe MAPI annonce la nomination de James M... [Published PR Newswire - Jan 07 2013]